FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
The market resolves based on the type of FDA approval granted to Anitocabtagene Autoleucel by Gilead Sciences in 2026.
KalshiEnds Dec 31, 2026Outcomes
Yes pays $1 if it happens · best price highlighted
| Outcome | Chance | 24h | Last 24h | Kalshi |
|---|---|---|---|---|
| a full approval or an accelerated approval | 89% | — | 92¢ |
a full approval or an accelerated approval
89%
—Yes price on Kalshi, last 2 weeks
Discussion
Posts and calls about this event
Live room
Connecting…Loading…
Sign in to chat in the room.